Back to News
Mar 16, 2026 12:10 AM

Kelyniam Global Reports 2025 Financial Results

Strong Second-Half Momentum Drives 85% Net Loss Improvement; FDA Clearance Secured for Innovative Fusion™ Biomaterial Implant; Board Rejects Undervalued Acquisition Interest

CANTON, Conn., March 16, 2026 /PRNewswire/ -- Kelyniam Global (OTC:KLYG), a leader in custom cranial implants, today announced its financial results for the year ended December 31, 2025.

"Despite a challenging start to last year, our team delivered a strong rebound in the second half while achieving meaningful bottom-line progress through continued expense management," said Ross Bjella, CEO of Kelyniam Global. "We are especially pleased with the 85% improvement in net loss, reflecting the strength of our core business model, the elimination of prior-year one-time charges, and sales across our innovative product portfolio. These results demonstrate our ability to respond to market conditions and we remain confident in our path forward."

Financial Highlights (Year ended December 31, 2025 vs. December 31, 2024)

Total revenue of $3,053,222, an ...